Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 19/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15446070 | 0.87 | IRAK4 (0.48) | IRAK4 | |
| SCHEMBL5916856 | 0.81 | TRPV1 (0.41) | ABL1BCR | |
| SCHEMBL5916959 | 0.81 | TRPV1 (0.41) | ABL1BCR | |
| SCHEMBL5916920 | 0.81 | TRPV1 (0.41) | ABL1BCR | |
| SCHEMBL5917125 | 0.79 | ABL1 (0.37) | ABL1BCR | |
| SCHEMBL1012572 | 0.79 | ABL1 (0.46) | IRAK4ABL1BCR | |
| SCHEMBL3915434 | 0.78 | DYRK1A (0.41) | IRAK4 | |
| SCHEMBL5916866 | 0.78 | APOB (0.39) | ABL1BCR | |
| SCHEMBL4621959 | 0.77 | LIPC (0.41) | — | |
| SCHEMBL1013512 | 0.77 | ABL1 (0.61) | ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542692-B1 | AMINOPYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC (US) | 2011-01-05 | — | — | EP | claimed |
| US-7053088-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-05-30 | — | — | US | claimed |
| EP-1542692-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | Amgen Inc. (US) | 2005-06-22 | — | — | EP | claimed |
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-02-26 | — | — | US | claimed |
| WO-2003099284-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC. (US) | 2003-12-04 | — | — | WO | claimed |
| US-20250186375-A1 | TREATMENT FOR HOT FLUSHES | DIGNITY HEALTH | 2025-06-12 | — | — | US | disclosed |
| US-12257216-B2 | Treatment for hot flushes | DIGNITY HEALTH (US) | 2025-03-25 | — | — | US | disclosed |
| CN-115244043-B | Benzimidazolone cinnamamide derivatives as TRPV1 antagonists and pharmaceutical composition for treating or preventing pain containing the same as active ingredient | 杰迈肯有限公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-4095133-B1 | BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT | JMACKEM CO LTD (KR) | 2024-07-24 | — | — | EP | disclosed |
| US-20230147428-A1 | BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT | JMACKEM CO., LTD (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230135909-A1 | NOVEL TREATMENT FOR HOT FLUSHES | DIGNITY HEALTH | 2023-05-04 | — | — | US | disclosed |
| EP-4095133-A1 | BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT | Jmackem Co., Ltd (KR) | 2022-11-30 | — | — | EP | disclosed |
| US-7396831-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396831-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7053088-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050277646-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050267163-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-01 | — | — | US | disclosed |
| EP-1542692-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | Amgen Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2003099284-A1 | AMINO-PYRIDINE, -PYRIDINE AND PYRIDAZINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12257216-B2 | Treatment for hot flushes | TRPV1, TRPA1, TRPV2 | IRAK4 3751/4885ABL1 359/4885BCR 3721/4885 |
| US-20250186375-A1 | TREATMENT FOR HOT FLUSHES | TRPV1, TRPA1, TRPV2 | IRAK4 3751/4885ABL1 359/4885BCR 3721/4885 |
| US-20040038969-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | IRAK4 1364/4885ABL1 1496/4885BCR 630/4885 |
| US-20050267163-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | IRAK4 1572/4885ABL1 1443/4885BCR 587/4885 |
| US-20230147428-A1 | BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT | TRPV1, TRPA1, TRPV5 | IRAK4 566/4885ABL1 1557/4885BCR 1410/4885 |
| US-20230135909-A1 | NOVEL TREATMENT FOR HOT FLUSHES | TRPV1, TRPA1, TRPV2 | IRAK4 3329/4885ABL1 497/4885BCR 3588/4885 |
| US-20050277646-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | IRAK4 1572/4885ABL1 1443/4885BCR 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.